Search Result
Results for "
adrenergic blocking
" in MedChemExpress (MCE) Product Catalog:
21
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0203A
-
|
R 065824 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
|
-
-
- HY-B0203
-
|
R 065824
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
|
-
-
- HY-B1392
-
-
-
- HY-103214
-
-
-
- HY-16316
-
-
-
- HY-108247
-
-
-
- HY-U00016
-
-
-
- HY-100141
-
-
-
- HY-101656A
-
|
RMI81968 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Medroxalol hydrochloride is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol hydrochloride shows antihypertensive and vasodilating effects .
|
-
-
- HY-B1392S
-
-
-
- HY-12717A
-
-
-
- HY-101656
-
|
RMI81968
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects .
|
-
-
- HY-U00386
-
-
-
- HY-118470
-
|
Butoxamin hydrochloride
|
Adrenergic Receptor
|
Endocrinology
|
|
Butaxamine (Butoxamin) hydrochloride is a specific β2-adrenergic receptor blocker. Butaxamine hydrochloride inhibits the decreases in urine volume in ethanol-anesthetized, water-diuretic rats .
|
-
-
- HY-B0804S
-
-
-
- HY-B0381B
-
-
-
- HY-129436
-
-
-
- HY-106554A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Trimazosin hydrochloride hydrate is an orally active, quinazoline derivative which is structurally related to prazosin. Trimazosin shows hypotensive effect by selectively block α1-adrenergic receptor .
|
-
-
- HY-B0381A
-
-
-
- HY-105154A
-
-
-
- HY-B0193AS
-
-
-
- HY-B0381
-
-
-
- HY-14607
-
|
HP 749
|
Potassium Channel
|
Neurological Disease
|
Besipirdine (hydrochloride) is a potassium channel blocker with cholinergic and adrenergic activity. The cholinergic activity of Besipirdine (hydrochloride) involves stimulating phosphatidylinositol turnover and reducing potassium currents. The adrenergic activity of Besipirdine (hydrochloride) involves stimulating norepinephrine release, which is attributed to the inhibition of presynaptic α2-adrenergic receptors and the inhibition of norepinephrine uptake. Besipirdine (hydrochloride) may be used in research for Alzheimer's disease .
|
-
-
- HY-19022
-
-
-
- HY-102032
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
Butyryltimolol, an effective precursor of Timolol, improves the corneal penetration of Timolol . Butyryltimolol is a β-adrenergic blocker .
|
-
-
- HY-113858
-
-
-
- HY-108306
-
-
-
- HY-123449A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
MK-761 TFA is a potent and orally active β2-adrenergic blocker. MK-761 TFA shows antihypertensive and positive inotropic effects. MK-761 TFA shows vasodilating properties .
|
-
-
- HY-17498B
-
|
(RS)-Atenolol hydrochloride; Tenormin hydrochloride; ICI 66082 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Neurological Disease
Endocrinology
Cancer
|
|
Atenolol hydrochloride is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol hydrochloride can be used for the research of hypertension and angina pectoris .
|
-
-
- HY-102032A
-
|
|
Adrenergic Receptor
|
Others
|
|
(RS)-Butyryltimolol is the racemate of Butyryltimolol. Butyryltimolol, an effective proagent of Timolol, improves the corneal penetration of Timolol . Butyryltimolol is a β-adrenergic blocker .
|
-
-
- HY-108286
-
|
Cordanum
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity .
|
-
-
- HY-136693
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
L-654284 is an α2-adrenergic receptor antagonist with significant selectivity. L-654284 competes with the binding of 3H-clonidine and 3H-rauwolscine in vitro and shows Ki values of 0.8 nM and 1.1 nM, respectively. L-654284 can block the protrusion effect of clonidine in isolated vas deferens in rats, with a pA2 value of 9.1. L-654284 exhibits remarkable selectivity for α2 and α1 adrenergic receptors, and exhibits a Ki of 110 nM in inhibiting 3H-prazosin binding. L-654284 can significantly increase the turnover rate of norepinephrine in rat cerebral cortex in vivo, showing α2-adrenergic receptor blocking activity in the central nervous system .
|
-
-
- HY-135004
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
Su-4029 is an agent that interacts with alpha receptors. It negates the blockade of norepinephrine by the reversible adrenergic blocker phentolamine but not by the irreversible blocker Dibenamine, suggesting Su-4029 acts at the same site as these blockers. Su-4029 pretreatment results in three categories of responses to pressor phenylalkylamines: irreversible blockade of amines with no or only p-hydroxylation, reversible blockade of amines with beta-carbon hydroxylation, and no blockade or augmentation of amines with m and p-hydroxylation or m or p plus beta-hydroxylation. Su-4029 may deform the alpha receptor site affected by adrenergic blocking agents .
|
-
-
- HY-B0076S
-
-
-
- HY-17498
-
-
-
- HY-123449
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
MK-761 free base is a potent and orally active β2-adrenergic blocker. MK-761 free base shows antihypertensive and positive inotropic effects. MK-761 free base shows vasodilating properties .
|
-
-
- HY-A0252A
-
|
|
Adrenergic Receptor
|
Cancer
|
|
Bupranolol hydrochloride is a non-selective β-adrenergic blocker with potent membrane stabilizing activity. Bupranolol hydrochloride is able to significantly modulate the contractile activity of the non-pregnant human uterus. Bupranolol hydrochloride showed significant effects on spontaneous uterine contractions in an in vitro study in patients with ovarian cancer. Bupranolol hydrochloride is similar in potency to propranolol, another β-adrenergic blocker. Bupranolol hydrochloride is rapidly and completely absorbed in vivo, and its major metabolite is carboxybupranolol .
|
-
-
- HY-129029
-
-
-
- HY-120829
-
-
-
- HY-B0381S
-
-
-
- HY-B0381AS
-
|
SL75212-d7
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Betaxolol-d7 (hydrochloride) is the deuterium labeled Betaxolol hydrochloride. Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
|
-
-
- HY-100796
-
|
Vatensol
|
Dopamine β-hydroxylase
|
Cardiovascular Disease
|
|
Guanoclor is an antihypertensive compound. Guanoclor is an adrenergic neurone-blocking agent, which also interferes with noradrenaline synthesis by inhibition of the enzyme dopamine beta-hydroxylase .
|
-
-
- HY-103196
-
-
-
- HY-108302
-
|
|
Adrenergic Receptor
|
Others
|
|
Nifenalol is a β-adrenergic receptor blocker. Nifenalol inhibits β-adrenoceptor differentiation in right atrium, diaphragm and adipose tissue in a rat model .
|
-
-
- HY-B0800
-
-
-
- HY-121902
-
|
|
Adrenergic Receptor
|
Others
|
|
Butidrine is a compound with intraocular pressure-lowering activity that is less effective than some other beta-adrenergic receptor blockers in reducing intraocular pressure in rabbit eyes.
|
-
-
- HY-B1392A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Esmolol is a potent and cardio-selective β-adrenergic blocker. Esmolol shows cardioprotection. Esmolol has the potential for the research of tachycardia with ischemic heart disease .
|
-
-
- HY-B0076
-
-
-
- HY-167698
-
-
-
- HY-139727A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
S(-)-Bisoprolol fumarate is a S(-)-enantiomer of Bisoprolol fumarate. Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
|
-
- HY-139727
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
S(-)-Bisoprolol is a S(-)-enantiomer of Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
|
-
- HY-B0437
-
|
MJ 1999
|
Adrenergic Receptor
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .
|
-
- HY-128380
-
|
N-(2-Chloroethyl)dibenzylamine hydrochloride
|
Adrenergic Receptor
|
Metabolic Disease
|
|
Dibenamine hydrochloride is a competitive and irreversible adrenergic blocking agent and is known to modify the pharmacological effects of epinephrine. Dibenamine hydrochloride cause a significant increase in the rate of destruction of I-epinephrine in the mouse .
|
-
- HY-B0381R
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Betaxolol (Standard) is the analytical standard of Betaxolol. This product is intended for research and analytical applications. Betaxolol is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
|
-
- HY-B0381AR
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Betaxolol (hydrochloride) (Standard) is the analytical standard of Betaxolol (hydrochloride). This product is intended for research and analytical applications. Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
|
-
- HY-B0193S
-
-
- HY-108286S
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
|
|
(Rac)-Talinolol-d5 is the racemate of Talinolol. Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity[1][2][3].
|
-
- HY-W707407
-
-
- HY-17498S
-
|
(RS)-Atenolol-d7
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Atenolol-d7 is the deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].
|
-
- HY-105699
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
Napamezole is an α2A adrenergic receptor antagonist and a serotonin/norepinephrine uptake inhibitor. Napamezole increases the levels of monoamines in the brain by blocking monoamine uptake, which gives it antidepressant activity .
|
-
- HY-W726392
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
N-Nitrosometoprolol is an N-nitroso derivative formed by the in vitro reaction of β-adrenergic blockers with sodium nitrite. N-Nitrosometoprolol can induce micronuclei in rat liver, bone marrow and spleen .
|
-
- HY-129029S
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Bisoprolol-d5 is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research[1][2].
|
-
- HY-17498R
-
|
(RS)-Atenolol (Standard)
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
Cancer
|
|
Atenolol (Standard) is the analytical standard of Atenolol. This product is intended for research and analytical applications. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris .
|
-
- HY-101690
-
-
- HY-B0437AS
-
|
MJ 1999-d6 hydrochloride
|
Adrenergic Receptor
Potassium Channel
|
Cardiovascular Disease
Endocrinology
|
|
Sotalol-d6 (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels[1][2].
|
-
- HY-129029R
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Bisoprolol (Standard) is the analytical standard of Bisoprolol. This product is intended for research and analytical applications. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
|
-
- HY-B0437S
-
-
- HY-106523
-
|
KT 210; K 351; Hypadil
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nipradolol (KT-210; K-351) is a potent blocker of alpha-1-adrenergic receptors. Nipradolol inhibits the increase of intraocular pressure (IOP) in an albino rabbit model induced by Phenylephrine (HY-B0769). Nipradolo suppresses the noradrenaline (NA)-induced muscles contraction, also exhibits vasodilator activity on the dog coronary artery .
|
-
- HY-121578
-
|
GDHB
|
Adrenergic Receptor
|
Neurological Disease
|
|
Agaridoxin (GDHB) is a blocker of catecholamine and adrenergic alpha-type receptors isolated from mushrooms. Agaridoxin activates adenylyl cyclase in rat hypothalamic membrane granules in the presence of guanosyl imide diphosphate (Gpp(NH)p) .
|
-
- HY-B0532
-
|
|
Dopamine Receptor
Adrenergic Receptor
P-glycoprotein
CaMK
Influenza Virus
Autophagy
|
Neurological Disease
|
|
Trifluoperazine, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine is a potent α1-adrenergic receptor antagonist. Trifluoperazine is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine can be used for the research of schizophrenia. Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis .
|
-
- HY-B0532A
-
|
|
Dopamine Receptor
Adrenergic Receptor
CaMK
P-glycoprotein
Influenza Virus
Autophagy
|
Neurological Disease
Cancer
|
|
Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis .
|
-
- HY-P10773
-
-
- HY-B0437R
-
|
|
Adrenergic Receptor
Potassium Channel
|
Cardiovascular Disease
Neurological Disease
|
|
Sotalol (hydrochloride) (Standard) is the analytical standard of Sotalol (hydrochloride). This product is intended for research and analytical applications. Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .
|
-
- HY-126562R
-
|
|
Bacterial
Fungal
Antibiotic
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Sotalol (hydrochloride) (Standard) is the analytical standard of Sotalol (hydrochloride). This product is intended for research and analytical applications. Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .
|
-
- HY-B0982
-
-
- HY-127128
-
|
ACC-9089 sulfate
|
Adrenergic Receptor
|
Neurological Disease
|
|
Flestolol (ACC-9089) sulfate is a competitive, ultra-short-acting beta-adrenergic blocking agent. Flestolol sulfate shows a half-life of approximately 6.5 minutes. Flestolol sulfate has the potential for the research of chest pain .
|
-
- HY-122212
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
PF-9404C is a potent beta-adrenergic blocker and a vasorelaxing agent. PF-9404C can be used as NO-donor. PF-9404C shows antihypertensive and cardioprotective action .
|
-
- HY-122537
-
|
|
Adrenergic Receptor
5-HT Receptor
|
Cardiovascular Disease
|
|
Arotinolol hydrochloride is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol hydrochloride also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites . Arotinolol hydrochloride is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
|
-
- HY-122537A
-
|
|
Adrenergic Receptor
5-HT Receptor
|
Cardiovascular Disease
|
|
Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
|
-
- HY-B0799
-
|
Ergoloid mesylates
|
GABA Receptor
Chloride Channel
Adrenergic Receptor
Dopamine Receptor
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Neurological Disease
|
|
Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABAA receptor associated Cl - channel. Dihydroergotoxine mesylate also interacts with central dopaminergic and serotonergic receptors. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity .Dihydroergotoxine mesylate (Ergoloid mesylates) is an α-adrenergic blocking agent. Dihydroergotoxine mesylate binds with high affinity to the GABAA receptor associated Cl - channel. Dihydroergotoxine mesylate also interacts with central dopaminergic and serotonergic receptors. Dihydroergotoxine mesylate displays antiproliferative, antihypertensive and neuroprotective activity .
|
-
- HY-B0532AS
-
|
|
Isotope-Labeled Compounds
Dopamine Receptor
Adrenergic Receptor
CaMK
P-glycoprotein
Influenza Virus
Autophagy
|
Neurological Disease
Cancer
|
|
Trifluoperazine-d3 (dihydrochloride) is deuterium labeled Trifluoperazine (dihydrochloride). Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis[1][2][3][4][5].
|
-
- HY-B0532B
-
|
|
Dopamine Receptor
Adrenergic Receptor
P-glycoprotein
CaMK
Influenza Virus
Autophagy
|
Infection
Neurological Disease
Cancer
|
|
Trifluoperazine dimaleate, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dimaleate is a potent α1-adrenergic receptor antagonist. Trifluoperazine dimaleate is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dimaleate is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dimaleate can be used for the research of schizophrenia. Trifluoperazine dimaleate acts as a reversible inhibitor of influenza virus morphogenesis .
|
-
- HY-B0800R
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
Guanethidine (sulfate) (Standard) is the analytical standard of Guanethidine (sulfate). This product is intended for research and analytical applications. Guanethidine sulfate (Guanethidine monosulfate), an antihypertensive agent, is an adrenergic neurone blocking agent. Guanethidine sulfate enters noradrenergic nerve terminals by the neuronal amine carrier .
|
-
- HY-16094
-
|
BW 467C60
|
Adrenergic Receptor
|
Neurological Disease
|
|
Bethanidine sulfate and its ortho-chloro derivative (BW 392C60) are potent adrenergic neurone blockers with sympathomimetic effects similar to bretylium and guanethidine in various animal models, particularly in cats. They inhibit the release of noradrenaline during nerve stimulation and enhance smooth muscle responses to adrenaline and noradrenaline. Bethanidine sulfate increases pressor responses to tyramine, though this effect diminishes with higher doses. Unlike guanethidine, Bethanidine sulfate does not deplete pressor amine content in the iris of cats post-administration. It also briefly inhibits autonomic cholinergic mechanisms and causes temporary neuromuscular paralysis in large doses, contrasting with its prolonged adrenergic neurone blocking effects .
|
-
- HY-126028A
-
-
- HY-106476
-
|
UK-11443
|
Adrenergic Receptor
Bacterial
Antibiotic
|
Infection
Cardiovascular Disease
|
|
Primidolol (UK-11443), derived from Parmotrema perlatum, possesses antibacterial and antioxidant activities. Primidolol is also an orally active α/β Adrenergic Receptor blocker with antihypertensive activity.
Primidolol can be used in research related to infections and cardiovascular diseases .
|
-
- HY-119706
-
|
|
Apoptosis
Arrestin
|
Others
|
|
Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis .
|
-
- HY-W030796R
-
|
|
Taste Receptor
|
Metabolic Disease
|
|
Trifluoperazine (dihydrochloride) (Standard) is the analytical standard of Trifluoperazine (dihydrochloride). This product is intended for research and analytical applications. Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis .
|
-
- HY-B0532AR
-
|
|
Dopamine Receptor
Adrenergic Receptor
CaMK
P-glycoprotein
Influenza Virus
Autophagy
|
Neurological Disease
Cancer
|
|
Trifluoperazine (dihydrochloride) (Standard) is the analytical standard of Trifluoperazine (dihydrochloride). This product is intended for research and analytical applications. Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis .
|
-
- HY-B1435A
-
|
Thymoxamine
|
Adrenergic Receptor
|
Neurological Disease
|
|
Moxisylyte (Thymoxamine) is an alpha 1-selective antagonist with activity that improves bladder emptying. Moxisylyte is used to suppress urinary difficulties in patients with multiple system atrophy (MSA) by blocking alpha 1-adrenergic receptors to reduce the amount of residual urine after urination. Moxisylyte is also used to suppress erectile dysfunction and can improve blood circulation problems caused by Raynaud's syndrome in the short term. In addition, Moxisylyte can be applied topically to the eye to reverse the mydriasis caused by phenylephrine and other sympathetic stimulants .
|
-
- HY-106667
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
DL 071IT is a potent non-selective beta-adrenergic receptor blocker. DL 071IT exhibits intrinsic sympathomimetic activity and weak membrane stabilizing activity. DL 071IT reduces exercise heart rate and systolic blood pressure, and even significantly lowers resting heart rate .
|
-
- HY-B1396
-
|
BMY-13754; MJ-13754-1
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity .
|
-
- HY-B0804
-
Nadolol
2 Publications Verification
SQ-11725
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .
|
-
- HY-B0203AR
-
|
R 065824 hydrochloride (Standard)
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Nebivolol (hydrochloride) (Standard) is the analytical standard of Nebivolol (hydrochloride). This product is intended for research and analytical applications. Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
|
-
- HY-B0362A
-
|
Phentolamine methanesulfonate
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine mesylate can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction .
|
-
- HY-W653969
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
5-HT Receptor
|
Cardiovascular Disease
|
|
Arotinolol-d5 (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
|
-
- HY-B0982R
-
|
LB-46 (Standard)
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Pindolol (Standard) is the analytical standard of Pindolol. This product is intended for research and analytical applications. Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (Ki=33nM).
|
-
- HY-100952
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nifenalol hydrochloride is a β-adrenergic receptor antagonist. Nifenalol hydrochloride induces the Early Afterdepolarization (EAD) effect. EAD is a phenomenon in cardiac electrophysiology that usually occurs during an action potential in ventricular muscle cells and can lead to arrhythmia. The EAD effect of Nifenalol hydrochloride can be blocked by Tetrodotoxin. Nifenalol hydrochloride is used in the study of conditions such as irregular heartbeat or high blood pressure .
|
-
- HY-B1396S
-
|
BMY-13754-d6; MJ-13754-1-d6
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Nefazodone-d6 (hydrochloride) is the deuterium labeled Nefazodone hydrochloride. Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].
|
-
- HY-B1396S1
-
|
BMY-13754-d6 dihydrochloride; MJ-13754-1-d6 dihydrochloride
|
Isotope-Labeled Compounds
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Nefazodone-d6 (dihydrochloride) is deuterium labeled Nefazodone (hydrochloride). Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].
|
-
- HY-12717AS
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
|
Phentolamine-d4 (hydrochloride) is the deuterium labeled Phentolamine hydrochloride. Phentolamine hydrochloride is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine hydrochloride can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction[1][2][3].
|
-
- HY-B0804R
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nadolol (Standard) is the analytical standard of Nadolol. This product is intended for research and analytical applications. Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .
|
-
- HY-B1396R
-
|
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
|
Nefazodone (hydrochloride) (Standard) is the analytical standard of Nefazodone (hydrochloride). This product is intended for research and analytical applications. Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity .
|
-
- HY-B0362AR
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phentolamine (mesylate) (Standard) is the analytical standard of Phentolamine (mesylate). This product is intended for research and analytical applications. Phentolamine mesylate (Phentolamine methanesulfonate) is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine mesylate can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction .
|
-
- HY-A0016
-
|
SR 33589
|
mAChR
Sodium Channel
Calcium Channel
Adrenergic Receptor
Cytochrome P450
Autophagy
|
Cardiovascular Disease
|
|
Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4 .
|
-
- HY-19012
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
N-1518 is an α and β adrenergic receptor blocker that has competitive antagonism against β1 and α1 receptors, but does not show selectivity for β1 receptors, but shows about 20-fold selectivity for α1 receptors. N-1518 has vasodilatory effects and can be used in the research field of hypertension treatment .
|
-
- HY-B0982S
-
-
- HY-A0016R
-
|
|
mAChR
Sodium Channel
Calcium Channel
Adrenergic Receptor
Cytochrome P450
Autophagy
|
Cardiovascular Disease
|
|
Dronedarone (Standard) is the analytical standard of Dronedarone. This product is intended for research and analytical applications. Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4 .
|
-
- HY-A0016S
-
|
|
mAChR
Sodium Channel
Calcium Channel
Adrenergic Receptor
Cytochrome P450
Autophagy
|
Cardiovascular Disease
|
|
Dronedarone-d6 (hydrochloride) is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone hydrochloride is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone hydrochloride is a substrate for and a moderate inhibitor of CYP3A4[1][2][3][4].
|
-
- HY-117181
-
|
|
Phosphodiesterase (PDE)
Adrenergic Receptor
|
Cardiovascular Disease
|
|
UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .
|
-
- HY-W650803
-
|
A-57219
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nemazoline (A-57219) is selective α-adrenergic agent with α1-agonist/α2-antagonist activity, which is used as a nasal decongestant. Nemazoline produces decongestion by α1-mediated contraction of capacitance vessels, but not compromises blood flow by virtue of α2-antagonism. Nemazoline also blocks endogenous noradrenaline-mediated α 2-constriction of the resistance vessels .
|
-
- HY-112461
-
|
|
P2X Receptor
|
Cardiovascular Disease
|
|
NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a Gsα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
|
-
- HY-112461A
-
|
|
P2X Receptor
|
Cardiovascular Disease
|
|
NF449 octasodium is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 octasodium is a Gsα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
|
-
- HY-10122
-
|
KAD 3213; KMD 3213
|
Adrenergic Receptor
Bacterial
|
Endocrinology
Cancer
|
|
Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .
|
-
- HY-10122S
-
|
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Endocrinology
Cancer
|
|
Silodosin-d4 is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH[1][3].
|
-
- HY-10122R
-
|
|
Adrenergic Receptor
Bacterial
|
Endocrinology
Cancer
|
|
Silodosin (Standard) is the analytical standard of Silodosin. This product is intended for research and analytical applications. Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0804S
-
|
|
|
Nadolol-d9 is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active β-adrenergic receptors blocker[1].
|
-
-
- HY-B0193AS
-
|
|
|
Prazosin-d8 hydrochloride is the deuterium labeled Prazosin hydrochloride. Prazosin hydrochloride is an alpha-adrenergic blocker .
|
-
-
- HY-B0193S
-
|
|
|
Prazosin-d8 is the deuterium labeled Prazosin. Prazosin is an alpha-adrenergic blocker and is a sympatholytic drug used to treat high blood pressure and anxiety, PTSD, and panic disorder.
|
-
-
- HY-17498S
-
|
|
|
Atenolol-d7 is the deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].
|
-
-
- HY-B1392S
-
|
|
|
Esmolol-d7 (hydrochloride) is the deuterium labeled Esmolol hydrochloride. Esmolol hydrochloride is a beta adrenergic receptor blocker[1][2].
|
-
-
- HY-B0076S
-
|
|
|
Bisoprolol-d7 (hemifumarate) is the deuterium labeled Bisoprolol hemifumarate. Bisoprolol hemifumarate is a selective type β1 adrenergic receptor blocker.
|
-
-
- HY-B0381S
-
|
|
|
Betaxolol-d5 is the deuterium labeled Betaxolol. Betaxolol is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
|
-
-
- HY-B0381AS
-
|
|
|
Betaxolol-d7 (hydrochloride) is the deuterium labeled Betaxolol hydrochloride. Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.
|
-
-
- HY-108286S
-
|
|
|
(Rac)-Talinolol-d5 is the racemate of Talinolol. Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity[1][2][3].
|
-
-
- HY-W707407
-
|
|
|
Bisoprolol-d7 is deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
|
-
-
- HY-129029S
-
|
|
|
Bisoprolol-d5 is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research[1][2].
|
-
-
- HY-B0437AS
-
|
|
|
Sotalol-d6 (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels[1][2].
|
-
-
- HY-B0437S
-
|
|
|
Sotalol-d6 is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3][4].
|
-
-
- HY-B0532AS
-
|
|
|
Trifluoperazine-d3 (dihydrochloride) is deuterium labeled Trifluoperazine (dihydrochloride). Trifluoperazine dihydrochloride, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dihydrochloride is a potent α1-adrenergic receptor antagonist. Trifluoperazine dihydrochloride is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dihydrochloride is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dihydrochloride can be used for the research of schizophrenia. Trifluoperazine dihydrochloride acts as a reversible inhibitor of influenza virus morphogenesis[1][2][3][4][5].
|
-
-
- HY-W653969
-
|
|
|
Arotinolol-d5 (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
|
-
-
- HY-B1396S
-
|
|
|
Nefazodone-d6 (hydrochloride) is the deuterium labeled Nefazodone hydrochloride. Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].
|
-
-
- HY-B1396S1
-
|
|
|
Nefazodone-d6 (dihydrochloride) is deuterium labeled Nefazodone (hydrochloride). Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity[1][2].
|
-
-
- HY-12717AS
-
|
|
|
Phentolamine-d4 (hydrochloride) is the deuterium labeled Phentolamine hydrochloride. Phentolamine hydrochloride is a reversible, non-selective, and orally active blocker of α1 and α2 adrenergic receptor that expands blood vessels to reduce peripheral vascular resistance. Phentolamine hydrochloride can be used for the research of pheochromocytoma-related hypertension, heart failure and erectile dysfunction[1][2][3].
|
-
-
- HY-B0982S
-
|
|
|
Pindolol-d7 (LB-46-d7) is the deuterium labeled Pindolol. Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (Ki=33 nM)[1][2].
|
-
-
- HY-A0016S
-
|
|
|
Dronedarone-d6 (hydrochloride) is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone hydrochloride is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone hydrochloride is a substrate for and a moderate inhibitor of CYP3A4[1][2][3][4].
|
-
-
- HY-10122S
-
|
|
|
Silodosin-d4 is the deuterium labeled Silodosin. Silodosin (KAD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH[1][3].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
